MultiCell inks deal with drug-component supplier

SAN DIEGO – MultiCell Technologies Inc. today announced that Merck KGaA & Co. Spittal/Drau Austria will formulate and supply an active component of MultiCell’s experimental chronic fatigue drug MCT-125.
The drug – successful thus far in clinical trials – is intended to treat fatigue in patients with multiple sclerosis (MS). No treatment has yet been approved by the U.S. Food & Drug Administration.
About 2 million people worldwide have MS, and about 10,000 new cases per year are diagnosed in the United States. More than 75 percent of MS patients report problems with chronic fatigue, and 50 to 60 percent say it is their worst symptom.
In a multi-center Phase II trial in three types of MS patients – conducted in the United Kingdom by Amarin Corp. plc, which developed the drug as LAX-202– MCT-125 significantly reduced fatigue in all three types of patients within four weeks. The patients reported few or no side effects.
Merk KGaA & Co. Spittal/Drau Austria (a href=”http://www.merck-spittal.at”>www.merck-spittal.at) is a maker of bulk and finished pharmaceutical products for third parties.
MultiCell Technologies Inc. (OTC BB: MCET.OB) is a biopharmaceutical company focusing on the development of new drugs and drug-development technologies. Additional information is available at www.multicelltech.com.